Table 1.
Treatment, cancer progression, ICI rechallenge and relapses according to the clinical presentation
| Myositis and/or NMJ disorders, n = 53 | Polyradiculoneuropathy, n = 23 | Sensory neuronopathy, n = 7 | Cranial neuritis, n = 10 | Meningoencephalitis, n = 19 | Limbic encephalitis, n = 16 | Myelitis, n = 8 | Cerebellar ataxia, n = 6 | Isolated meningitis, n = 8 | |
|---|---|---|---|---|---|---|---|---|---|
| ICI discontinuation, n/N (%) | 53/53 (100) | 23/23 (100) | 7/7 (100) | 10/10 (100) | 18/19 (94.7) | 16/16 (100) | 8/8 (100) | 6/6 (100) | 8/8 (100) |
| Immunological treatments, n/N (%) | |||||||||
| CCS | 50/52 (96.2) | 21/23 (91.3) | 6/6 (100) | 9/10 (90) | 16/19 (82.6) | 14/14 (100) | 8/8 (100) | 6/6 (100) | 7/8 (87.5) |
| IVIG | 10/52 (19.2) | 15/23 (65.2) | 6/6 (100) | 3/10 (10) | 5/19 (26.3) | 9/14 (64.3) | 3/8 (37.5) | 4/6 (66.7) | 1/8 (12.5) |
| PEX | 9/52 (17.3) | 3/23 (13.1) | 1/6 (16.7) | 1/10 (10) | 2/19 (10.5) | 2/14 (14.3) | 4/8 (50) | 0 (0) | 0/8 (0) |
| RTX | 0/52 (0) | 0/23 (0) | 1/6 (16.7) | 1/10 (10) | 0/19 (0) | 5/14 (35.7) | 0/8 (0) | 2 (33.3) | 0/8 (0) |
| CYC | 0/52 (0) | 1/23 (4.3) | 2/6 (33.3) | 0/10 (0) | 0/19 (0) | 1/14 (7.1) | 2/8 (25) | 1 (16.7) | 0/8 (0) |
| RUXO | 9/52 (17.3) | 0/23 (0) | 0/6 (0) | 0/10 (0) | 0/19 (0) | 0/14 (0) | 1/8 (12.5) | 0 (0) | 0/8 (0) |
| Median (range) follow-up duration, months | 11 (0.5–50) | 7 (0.5–38) | 14 (0.5–35) | 17.5 (3–38) | 13 (0.5–41) | 5.5 (0.5–31) | 14 (2–21) | 6.5 (0.5–47) | 27 (18.7–31.2) |
| Cancer progression, n/N (%) | 24/46 (52.2) | 10/20 (50) | 3/7 (42.9) | 3/10 (30) | 9/19 (47.4) | 7/14 (50.5) | 3/8 (37.5) | 2/6 (33.3) | 4/8 (50) |
| ICI rechallenge, n/N (%) | 4/46 (8.7) | 5/20 (25) | 1/6 (16.7) | 2/10 (20) | 3/18 (16.7) | 0/15 (0) | 0/8 (0) | 0/5 (0) | 2/8 (25) |
| n-irAE relapse, n/N (%) | 1/47 (2.1) | 3/22 (13.6) | 0/6 (0) | 0/10 (10) | 2/18 (11.1) | 2/13 (16.7) | 2/8 (25) | 1/5 (20) | 0/8 (0) |
Less frequent phenotypes (small-fiber neuropathy, n = 2, length-dependent polyneuropathy, n = 1, CIP, n = 1, neuromyotonia, n = 1) are not represented.
Abbreviations: CCS, corticosteroids; CYC, cyclophosphamide; IVIG, intravenous immunoglobulins; NMJ, neuromuscular junction; PEX, plasma exchange; RTX, rituximab; RUXO, ruxolitinib.